TITLE

Data Exclusivity: An Absolute Monopoly

AUTHOR(S)
Dabade, Gopal
PUB. DATE
July 2007
SOURCE
DESIDOC Bulletin of Information Technology;Jul2007, Vol. 27 Issue 4, p41
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The paper describes data exclusivity, its implication on generic drug manufacturers, and on cost of life-saving drugs in developing countries like India.
ACCESSION #
26664468

 

Related Articles

  • The times they are a-changin' for clinical trials data transparency. Moran, Nuala // BioWorld Today;1/7/2014, Vol. 25 Issue 4, p1 

    The article reports on the clinical trials data transparency and the access system which the biopharmaceutical industry has control of. It discusses the principles for clinical trial data sharing created by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and...

  • Drug Industry Wooed Politicians with Record $168M Last Year. Young, Donna // BioWorld Today;6/26/2008, Vol. 19 Issue 124, p1 

    The article focuses on the lobbying spending of the drug industry in 2007. Based on the report of the Center for Public Integrity, the three pharmaceutical companies that top the list are the Pharmaceutical Research and Manufacturers of America (PhRMA), Amgen Inc., and Pfizer Inc. The lobbying...

  • Patent expirations spell big changes for generic industry. Cassell, Dana K. // Drug Topics;8/6/2001 Supplement, Vol. 145 Issue 15, p9 

    Focuses on the increase of patent expirations among pharmaceutical industries in the United States. List of top eight drugs going off patent before December 2005; Delay of patent expiration due to court trials; Plan of an educational campaign on safety and efficacy of generic drugs.

  • Generics increase competition: study. J. G. D. // Medical Marketing & Media;Jun2007, Vol. 42 Issue 6, p17 

    The article reports the result of the study funded by PhRMA on competition among generic drug manufacturers in the U.S. According to the study, increasing use of authorized generics by drug companies has not led to delays in generic entry into the marketplace. PhRMA vice president for policy and...

  • PhRMA: petitions don't delay approval. J. G. D. // Medical Marketing & Media;Sep2007, Vol. 42 Issue 9, p16 

    The article reports on the Pharmaceutical Research and Manufacturers of America's (PhRMA) statement on the issue concerning the use of citizen petitions by drug companies to delay the U.S. Food and Drug Administration (FDA) approval of a generic drug. According to PhRMA, there is no sufficient...

  • Clinical Trials Code of Conduct. Messplay, Gary C.; Sampson, D. Kyle // Contract Pharma;2009, Vol. 11 Issue 7, p18 

    The article offers information on the newly revised code of conduct of the Pharmaceutical Research and Manufacturers of America (PhRMA). This code of conduct seeks to address concerns about both the safety of individuals participating in clinical drug trials and the integrity of clinical trial...

  • Patent Challenges. J. W. // Pharmaceutical Executive;Jun2007, Vol. 27 Issue 6, p24 

    The article reports that Thailand Government and other third-world nations are challenging patents on critical therapies, a tactic that is stepping up into a serious international confrontation over intellectual property protection. Thailand has been trying to override drug patents on AIDS...

  • Generic Pharmaceuticals: IP's Fiercest Litigation Arena. Andersen, Steven // Corporate Legal Times;Nov2003, Vol. 13 Issue 144, p28 

    Focuses on the complications in the generic drug application for patent rights by pharmaceutical companies in the U.S. Employment of strategy to extend the patent life of their products; Impact of the emergence of generic drugs on the pharmaceutical companies; Overview of the process of the...

  • Transparency, Fairness Needed For the Biosimilar Playing Field. Serebrov, Mari // BioWorld Today;6/20/2013, Vol. 24 Issue 118, p1 

    The article focuses on the concern of generic drugmakers in the U.S. regarding the impact of the delay of the U.S. Food and Drug Administration (FDA) in proposing schedule of biosimilar meetings and reviews on the interest of follow-on biologics (FOBs). It mentions that the late release of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics